🎉 M&A multiples are live!
Check it out!

Daewoong Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Daewoong Pharmaceutical and similar public comparables like Vivoryon Therapeutics, Julphar, and Pharming.

Daewoong Pharmaceutical Overview

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.


Founded

2002

HQ

South Korea
Employees

n/a

Website

daewoong.co.kr

Financials

LTM Revenue $975M

LTM EBITDA $141M

EV

$1.4B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Daewoong Pharmaceutical Financials

Daewoong Pharmaceutical has a last 12-month revenue of $975M and a last 12-month EBITDA of $141M.

In the most recent fiscal year, Daewoong Pharmaceutical achieved revenue of $969M and an EBITDA of $76.7M.

Daewoong Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Daewoong Pharmaceutical valuation multiples based on analyst estimates

Daewoong Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $937M $969M XXX XXX XXX
Gross Profit $435M $469M XXX XXX XXX
Gross Margin 46% 48% XXX XXX XXX
EBITDA $122M $76.7M XXX XXX XXX
EBITDA Margin 13% 8% XXX XXX XXX
Net Profit $28.8M $82.9M XXX XXX XXX
Net Margin 3% 9% XXX XXX XXX
Net Debt $229M $222M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Daewoong Pharmaceutical Stock Performance

As of April 15, 2025, Daewoong Pharmaceutical's stock price is KRW 132300 (or $90).

Daewoong Pharmaceutical has current market cap of KRW 1.52T (or $1.0B), and EV of KRW 2.06T (or $1.4B).

See Daewoong Pharmaceutical trading valuation data

Daewoong Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.4B $1.0B XXX XXX XXX XXX $3.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Daewoong Pharmaceutical Valuation Multiples

As of April 15, 2025, Daewoong Pharmaceutical has market cap of $1.0B and EV of $1.4B.

Daewoong Pharmaceutical's trades at 1.4x LTM EV/Revenue multiple, and 9.9x LTM EBITDA.

Analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Daewoong Pharmaceutical and 10K+ public comps

Daewoong Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.4B XXX XXX XXX
EV/Revenue 1.4x XXX XXX XXX
EV/EBITDA 18.3x XXX XXX XXX
P/E 61.5x XXX XXX XXX
P/E/Growth 0.4x XXX XXX XXX
EV/FCF -11.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Daewoong Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Daewoong Pharmaceutical Valuation Multiples

Daewoong Pharmaceutical's NTM/LTM revenue growth is 4%

Daewoong Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Daewoong Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Daewoong Pharmaceutical and other 10K+ public comps

Daewoong Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 3% XXX XXX XXX XXX
EBITDA Margin 8% XXX XXX XXX XXX
EBITDA Growth -37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 12% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 17% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 12% XXX XXX XXX XXX
Opex to Revenue 41% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Daewoong Pharmaceutical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Daewoong Pharmaceutical M&A and Investment Activity

Daewoong Pharmaceutical acquired  XXX companies to date.

Last acquisition by Daewoong Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Daewoong Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Daewoong Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Daewoong Pharmaceutical

When was Daewoong Pharmaceutical founded? Daewoong Pharmaceutical was founded in 2002.
Where is Daewoong Pharmaceutical headquartered? Daewoong Pharmaceutical is headquartered in South Korea.
Who is the CEO of Daewoong Pharmaceutical? Daewoong Pharmaceutical's CEO is Mr. Seng-ho Jeon.
Is Daewoong Pharmaceutical publicy listed? Yes, Daewoong Pharmaceutical is a public company listed on KRX.
What is the stock symbol of Daewoong Pharmaceutical? Daewoong Pharmaceutical trades under 069620 ticker.
When did Daewoong Pharmaceutical go public? Daewoong Pharmaceutical went public in 2002.
Who are competitors of Daewoong Pharmaceutical? Similar companies to Daewoong Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Daewoong Pharmaceutical? Daewoong Pharmaceutical's current market cap is $1.0B
What is the current revenue of Daewoong Pharmaceutical? Daewoong Pharmaceutical's last 12-month revenue is $975M.
What is the current EBITDA of Daewoong Pharmaceutical? Daewoong Pharmaceutical's last 12-month EBITDA is $141M.
What is the current EV/Revenue multiple of Daewoong Pharmaceutical? Current revenue multiple of Daewoong Pharmaceutical is 1.4x.
What is the current EV/EBITDA multiple of Daewoong Pharmaceutical? Current EBITDA multiple of Daewoong Pharmaceutical is 9.9x.
What is the current revenue growth of Daewoong Pharmaceutical? Daewoong Pharmaceutical revenue growth between 2023 and 2024 was 3%.
Is Daewoong Pharmaceutical profitable? Yes, Daewoong Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.